Evidence map›Paper›PMID 41091589›Full record

ArticleCancer2025

Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.

Anna Sicuranza, Paola Pacelli, Adele Santoni, Elisabetta Abruzzese, Daniele Cattaneo, Alessandra Iurlo, Luigiana Luciano, Sara Galimberti, Valentina Giai, Olga Mulas and 21 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Anna SicuranzaHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.ORCID https://orcid.org/0000-0002-5840-2956
Paola PacelliHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Adele SantoniHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Elisabetta AbruzzeseSant'Eugenio Hospital, Tor Vergata University, Rome, Italy.ORCID https://orcid.org/0000-0001-5228-6491
Daniele CattaneoHematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-7571-023X
Alessandra IurloHematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID https://orcid.org/0000-0002-4401-0812
Luigiana LucianoHematology-Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
Sara GalimbertiSection of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Valentina GiaiDivision of Hematology, Città Della Salute e Della Scienza, Turin, Italy.ORCID https://orcid.org/0009-0009-4238-1300
Olga MulasDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Giovanni CaocciDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Federica SoràDipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Isabella CapodannoSOC Ematologia Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Italy.
Monica CrugnolaEmatologia e Centro BMT, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Antonella GozziniHematology Unit, AOU Careggi, University of Florence, Florence, Italy.
Sabina RussoHematology, University of Messina, Messina, Italy.
Mario AnnunziataHematology Unit, Hospital 'Antonio Cardarelli', Naples, Italy.
Claudio FozzaDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Alessandra CartocciDepartment of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
Sara FredducciHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Emanuele PaciniHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Anna Marina LiberatiUniversità degli studi di Perugia-Struttura Complessa di Oncoematologia, Terni, Italy.
Marzia DefinaHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Elena BestosoHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Cristina MarzanoHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Dania TocciHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Teresa MiracapilloHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Camilla TurrizianiHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Katia PecciaHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Donatella RaspadoriHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.
Monica BocchiaHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy.

Funding

Associazione Italiana per la Ricerca sul Cancro-Investigator grant 20133Bando Salute Regione Toscana
6 · The paper itself

Abstract

backgroundThe authors previously demonstrated that in peripheral blood (PB) of chronic myeloid leukemia (CML), patients' leukemia stem cells (LSCs) CD26+ are detectable by flow cytometry at diagnosis, during tyrosine kinase inhibitor (TKI) therapy, and during treatment-free remission.

methodsThis study presents results of a prospective multicenter study including 242 newly diagnosed CML patients monitored for PB CD26+ leukemic stem cells (LSCs) quantification from diagnosis up to 24 months of TKI treatment.

resultsThe bulk of CD26+ LSCs at diagnosis varied between patients with a median value of 7.14 cells/µL. During TKI treatment, it has been observed their consistent and rapid reduction without statistical differences according to type of first-line TKI. Instead, a significant correlation between a low amount of CD26+ LSCs at diagnosis and an optimal molecular response at 3, 12, and 24 months was documented (p = .03, p = .004, and p = .009, respectively). Three tertiles of CD26+ LSCs correlating to molecular response were identified: <3.21 cells/µL; between 3.21 and 19.21 cells/µL; and >19.21 cells/µL. The incidence of patients with optimal response was higher in the first CD26+ LSCs tertile respect to the third one (p = .027, p = .015, and p = .079, respectively) at all time points (3, 12 and 24 months).

conclusionsThis study demonstrated a correlation between the amount of CD26+ LSCs at diagnosis and the molecular response, suggesting that the number of CD26+ LSCs at diagnosis could represent an additional tool for predicting TKI response.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsProtein Kinase InhibitorsAdultAgedAged, 80 and overDipeptidyl Peptidase 4FemaleFlow CytometryHumansMaleMiddle AgedProspective StudiesYoung AdultDipeptidyl Peptidase 4DPP4 protein, humanProtein Kinase InhibitorsCD26chronic myeloid leukemiaflow cytometryleukemia stem cellstyrosine kinase inhibitors

Identifiers

PMID41091589
PMCPMC12526715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.